BeOne Medicines Ltd.

BeOne Medicines AG is an oncology-focused biopharmaceutical company that discovers and develops targeted cancer treatments across multiple mechanisms of action. The company operates a commercial-stage portfolio alongside an extensive pipeline of clinical and preclinical candidates. Its approved products include BRUKINSA, a Bruton's Tyrosine Kinase inhibitor for blood cancers; TEVIMBRA, an anti-PD-1 immunotherapy for solid tumors and hematologic malignancies; and PARTRUVIX, a PARP inhibitor in development for solid tumors. The clinical pipeline encompasses multiple therapeutic modalities, including Bcl-2 inhibitors, bispecific antibodies, antibody-drug conjugates, degradation activation compounds, and small molecule inhibitors targeting pathways such as KRAS, CDK, EGFR, and FGFR.

The company maintains significant geographic reach across the United States, China, Europe, and other international markets. With approximately 11,000 full-time employees, BeOne Medicines operates at substantial scale within the biotechnology sector. The organization has established partnerships with major pharmaceutical companies including Amgen, Bristol Myers Squibb, Novartis, and others to advance drug development and commercialization efforts. The company was founded in 2010 under the name BeiGene, Ltd. and rebranded as BeOne Medicines AG in May 2025, maintaining its headquarters in Basel, Switzerland.